21 June 2019
Visiongain has launched a new pharma report Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis, Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
IBD incidence and prevalence is evolving worldwide and is now anticipated to be an emerging global disease. The inflammatory bowel diseases (IBD) drug market will continue to be driven by rising disease incidence and more-effective non-invasive diagnosis.
The lead analyst of the report commented "Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis. Economic development of newly industrialized countries is expected to intensify, and several developing countries will make the transition to the status of newly industrialized countries. The magnitude of the growth of IBD in newly industrialized countries will depend on several factors, including exposure to relevant environmental risk factors, urbanization of the population, access to health care, the speed of adoption of medical technologies such as colonoscopy, and natural population growth. Advances in electronic surveillance of diseases will also enhance reporting of IBD from many regions that currently lack data."
Leading companies featured in the report include AbbVie, Allergan, Biogen, Celgene Corporation, Gilead Sciences, Janssen, Novartis, Pfizer, Roche, Takeda, UCB Pharma S.A. and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.
05 July 2019
Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.
28 June 2019
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.
25 June 2019
Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.